Viridian Therapeutics (VRDN) to Release Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) will release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Viridian Therapeutics to post earnings of ($1.07) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.37). The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.15 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The business’s revenue was down 31.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.13) EPS. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Trading Up 5.6 %

Shares of NASDAQ:VRDN opened at $15.40 on Monday. The company has a quick ratio of 18.26, a current ratio of 18.26 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $16.73 and its 200 day moving average price is $17.61. The company has a market cap of $982.86 million, a PE ratio of -2.89 and a beta of 1.14. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $28.35.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VRDN. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Viridian Therapeutics in a report on Thursday, February 29th. Wedbush lifted their target price on Viridian Therapeutics from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. B. Riley decreased their price target on Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, March 20th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Viridian Therapeutics currently has an average rating of “Buy” and an average price target of $36.60.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.